Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,208 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Tumor Clear all
Completed Phase 1Phase 2 Interventional

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

NCT02206425
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Prednisone, Cyclophosphamide, Dexamethasone, Ascorbic acid, PLD, Lenalidomide, Pomalidomide
Drug · Dietary Supplement
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Bakersfield, California • Concord, California • Encinitas, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 15, 2026, 5:20 PM EDT
Active, not recruiting Phase 2 Interventional

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

NCT03071874
View directory record Official record
Conditions
Meningioma
Interventions
AZD2014
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

NCT00001059
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Filgrastim, Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 15, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

NCT05172596
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PHE885
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

NCT02391480
View directory record Official record
Conditions
Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML), Multiple Myeloma, Prostate Cancer, Small Cell Lung Cancer, Non-Hodgkins Lymphoma
Interventions
ABBV-075, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Influence of MMP on Brain AVM Hemorrhage

NCT00783523
View directory record Official record
Conditions
Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
Interventions
Doxycycline or Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 15, 2026, 5:20 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

NCT06142396
View directory record Official record
Conditions
Multiple Myeloma, Renal Failure
Interventions
Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
Combination Product
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00003960
View directory record Official record
Conditions
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

NCT01114282
View directory record Official record
Conditions
Multiple Myeloma
Interventions
velcade, Pralatrexate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

NCT01442090
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Everolimus, GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

NCT04176380
View directory record Official record
Conditions
Relapsed, Refractory Multiple Myeloma
Interventions
RAPA-201 Autologous T cells
Biological
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

NCT00096096
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
mycophenolate mofetil, tacrolimus
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

NCT01919086
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
Bortezomib, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
7
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 15, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

NCT00002880
View directory record Official record
Conditions
Lymphoma
Interventions
Etoposide phosphate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
4
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Paterson, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

NCT00571662
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease, Peripheral T-cell Lymphoma
Interventions
Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA), Mycophenolate Mofetil (MMF), G-CSF
Drug · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 15, 2026, 5:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

NCT07181941
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 5:20 PM EDT
Terminated Phase 1 Interventional

Phase I Study of CS-7017 and Bexarotene

NCT01504490
View directory record Official record
Conditions
Solid Tumors, Lymphoma, Multiple Myeloma
Interventions
CS-7017 and Bexarotene
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

NCT04000282
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
SAR442085
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

NCT00024466
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GVAX, Autologous transplant
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 15, 2026, 5:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

NCT00540566
View directory record Official record
Conditions
Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevi, Congenital Nevi, Seborrheic Keratosis, Paget's Disease, Dermatofibroma, Kaposi's Sarcoma, Port Wine Stain, Hemangioma, Tattoos, Scleroderma, Burns
Interventions
Optical Biopsy imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 15, 2026, 5:20 PM EDT
Completed Phase 2 Interventional

Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

NCT00142129
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Interventions
Bortezomib (Velcade)
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 15, 2026, 5:20 PM EDT
Completed No phase listed Observational

Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events

NCT05123001
View directory record Official record
Conditions
Hodgkin Lymphoma, Non Hodgkin Lymphoma, Leukemia, Multiple Myeloma
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 15, 2026, 5:20 PM EDT
Terminated Phase 1 Interventional

A Study of WVT078 in Patients With Multiple Myeloma (MM)

NCT04123418
View directory record Official record
Conditions
Multiple Myeloma (MM)
Interventions
WVT078, WHG626
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 15, 2026, 5:20 PM EDT